IRIS
ZANGHI', AURORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 576
NA - Nord America 343
AS - Asia 32
OC - Oceania 3
SA - Sud America 2
Totale 956
Salva come PNG Salva come JPEG
Nazione #
IE - Irlanda 381
US - Stati Uniti d'America 343
IT - Italia 75
SE - Svezia 71
FI - Finlandia 24
GB - Regno Unito 8
TR - Turchia 8
CN - Cina 7
IR - Iran 6
DE - Germania 5
HK - Hong Kong 5
BE - Belgio 3
IN - India 3
AU - Australia 2
CH - Svizzera 2
RO - Romania 2
AM - Armenia 1
AR - Argentina 1
BR - Brasile 1
DK - Danimarca 1
JP - Giappone 1
MD - Moldavia 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 956
Salva come PNG Salva come JPEG
Città #
Dublin 381
Chandler 87
Nyköping 70
Princeton 39
Wilmington 25
Helsinki 24
Des Moines 11
Ashburn 9
Kocaeli 8
Santa Clara 7
Milan 6
Naples 6
Seattle 6
Bari 4
Cedar Knolls 4
San Severo 4
Tehran 4
Tsuen Wan 4
London 3
Los Angeles 3
Norwalk 3
Rome 3
Washington 3
Ann Arbor 2
Catania 2
Gavere 2
Genoa 2
Guangzhou 2
Maslianico 2
Nanjing 2
New York 2
Orta Nova 2
Pimonte 2
Pisa 2
Potenza 2
Pune 2
Shenzhen 2
Spinazzola 2
Boardman 1
Brussels 1
Buenos Aires 1
Buffalo 1
Catanzaro 1
Cava de' Tirreni 1
Caxias do Sul 1
Central 1
Chicago 1
Chisinau 1
Clearwater 1
Coventry 1
Edinburgh 1
Foggia 1
Frankfurt am Main 1
Hangzhou 1
Jalandhar 1
Kemerovo 1
Kish 1
Logan 1
Melbourne 1
Misilmeri 1
Nara 1
Pinehaven 1
Pitesti 1
Reston 1
Ruvo di Puglia 1
Vancouver 1
Yerevan 1
Totale 773
Salva come PNG Salva come JPEG
Nome #
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 61
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 52
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 42
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 41
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 40
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 38
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 37
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 37
Can new chemical therapies improve the management of multiple sclerosis in children? 36
Management of dysphagia in multiple sclerosis: current best practice 35
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 33
An update on the safety of treating relapsing-remitting multiple sclerosis 30
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 27
Palliative care in progressive multiple sclerosis 26
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study 25
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 24
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 23
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 23
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 22
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 22
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 22
Switching therapy: how and why in a real word setting cohort of persons with multiple sclerosis in Catania 21
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 21
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 21
Real-world comparison of safety profile in two groups of relapsing remitting multiple sclerosis on dimethyl-fumarate and teriflunomide therapy: preliminary results of a multicenter, prospective study 21
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 20
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 20
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 20
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 20
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 19
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 19
Monocytic myeloid derived suppressor cells in hematological malignancies 19
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 18
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 18
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 17
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 17
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 17
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 16
Real-World comparison of reasons for changing treatment to dimethyl-fymarate or teriflunomide in non responders patients with relapsing remitting multiple sclerosis: preliminary results of a multicenter prospective study 16
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 16
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 16
Pharmacoeconomics of synthetic therapies for multiple sclerosis 16
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 14
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 14
Relapse-associated worsening in a real-life multiple sclerosis cohort: The role of age and pyramidal phenotype 13
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 12
Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study 9
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study 9
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 6
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 6
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 4
Neural precursor cells tune striatal connectivity through the release of IGFBPL1 4
New treatment targets in multiple sclerosis therapy 4
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey 3
Totale 1.182
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.173
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.173
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 0 0 0 0 24 0 1
2021/2022231 5 0 1 0 95 5 7 14 26 16 4 58
2022/2023722 60 18 39 47 14 44 2 37 413 19 17 12
2023/2024204 15 29 13 17 36 11 18 35 21 9 0 0
Totale 1.182